1.	A Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES) Phase: Phase IV Type: Natural history/Epidemiology Status: Active Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: AVF3991n, NCT00388206
2.	A Study to Evaluate Corrected QT Interval From Clinical Studies Conducted With Bevacizumab Phase: Phase IV Type: Supportive care, Treatment Status: Approved-not yet active Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: AVF4223g, NCT00477425
3.	PRIMADOS Study:A Study of Avastin (Bevacizumab) Plus Docetaxel for First Line Treatment of Patients With Metastatic Breast Cancer Phase: Phase IV Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML21343, NCT00774241
4.	Phase II/III Randomized Study of Neoadjuvant and Adjuvant Chemotherapy Comprising Epirubicin Hydrochloride, Cisplatin, and Capecitabine With or Without Bevacizumab in Patients With Previously Untreated, Resectable Gastric or Gastroesophageal Junction Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MRC-ST03, EU-20710, ISRCTN46020948, EUDRACT-2006-000811-12, CTA-00316/0221/001, NCT00450203
5.	Mesothelioma Avastin Plus Pemetrexed-cisplatin Study Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: IFCT-GFPC-ELCWP-0701, NCT00651456
6.	Phase II/III Randomized Study of Molecular Selection of Chemotherapy Using K-ras Mutation Analysis and Topoisomerase-1 Expression Analysis in Patients With Metastatic or Locally Advanced Colorectal Cancer Phase: Phase III, Phase II Type: Diagnostic, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UKM-MRC-FOCUS3-CR12, FOCUS 3 - CR12, EUDRACT-2008-008323-15, EU-20960, NCT00975897
7.	Bevacizumab in Extensive Small Cell Lung Cancer Phase: Phase III, Phase II Type: Treatment Status: Approved-not yet active Age: 18 to 75 Sponsor: Other Protocol IDs: IFCT-0802, 2009-010187-42, NCT00930891
8.	Phase III Randomized Study of Oxaliplatin, Leucovorin Calcium, and Fluorouracil With Versus Without Bevacizumab in Patients With Resected Stage II Colon Cancer and at High Risk for Recurrence Based on Molecular Markers Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-E5202, E5202, NCT00217737
9.	Phase III Randomized Study of Combination Chemotherapy Comprising Oxaliplatin, Leucovorin Calcium, and Fluorouracil (Modified FOLFOX) or Oxaliplatin and Capecitabine (XELOX) in Combination With Bevacizumab With Versus Without Erlotinib in Patients With Unresectable Metastatic Colorectal Adenocarcinoma Phase: Phase III Type: Treatment Status: Active Age: 18 to 80 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: GERCOR-C04-2, EU-20565, GERCOR-OPTIMOX3-TARCEVA, ROCHE-GERCOR-C04-2, NCT00265824, GERCOR-DREAM- C04-2
10.	Phase III Randomized Study of Cetuximab and/or Bevacizumab in Combination With Either Oxaliplatin, Fluorouracil, and Leucovorin Calcium (FOLFOX) OR Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium (FOLFIRI) in Patients With Previously Untreated Metastatic Adenocarcinoma of the Colon or Rectum (Arm III [Cetuximab and Bevacizumab in Combination With FOLFOX or FOLFIRI] Closed to Accrual as of 09/10/2009) Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-C80405, C80405, SWOG-C80405, NCT00265850
11.	Phase III Randomized Study of Adjuvant Chemotherapy With or Without Bevacizumab in Patients With Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-E1505, E1505, SWOG-E1505, CALGB-E1505, CAN-NCIC-E1505, NCCTG-E1505, NCT00324805
12.	Phase III Randomized Study of Six Different Neoadjuvant Chemotherapy Regimens With or Without Neoadjuvant and Adjuvant Bevacizumab in Women With Operable Stage I-IIIA Breast Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NSABP-B-40, NCT00408408
13.	A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer. Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BO20231, NCT00391092
14.	Adjuvant Xeloda Plus Eloxatin +/- Avastin After Radical Resection of Liver Metastasis of Colorectal Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: HEPATICA, NCT00394992
15.	5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC) Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: FIRE-3, NCT00433927
16.	A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AVF4095g, NCT00434642
17.	Maintenance Treatment Versus Observation After Induction in Advanced Colorectal Carcinoma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CAIRO3, NCT00442637
18.	Phase III Randomized Study of Adjuvant Chemotherapy Comprising Carboplatin and Paclitaxel With Versus Without Bevacizumab and/or Secondary Cytoreduction Surgery in Patients With Platinum-Sensitive Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: GOG-0213, GOG-0213, NCT00565851
19.	Phase III Randomized Study of Carboplatin and Paclitaxel With Versus Without Bevacizumab in Patients With Newly Diagnosed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: MREC-ICON7, EUDRACT-2005-003929-22, ISRCTN91273375, ROCHE-MREC-ICON7, EU-20730, ICON7, MREC-06/MRE02/52, NCT00483782
20.	Randomized Phase III Study of Folfiri+Avastin Versus Xeliri+Avastin as 1st Line Treatment of CRC Phase: Phase III Type: Treatment Status: Active Age: 18 to 72 Sponsor: Other Protocol IDs: CT/05.16, NCT00469443
21.	Phase III Randomized Study of Irinotecan Hydrochloride-Based Chemotherapy and Cetuximab With Versus Without Bevacizumab in Patients With Metastatic Colorectal Cancer That Progressed on First-Line Therapy (Treatment Arm III Closed to Accrual as of 4/20/2009) Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: SWOG-S0600, S0600, CALGB-SWOG-S0600, ECOG-SWOG-S0600, CAN-NCIC-SWOG-S0600, NCCTG-SWOG-S0600, NCT00499369
22.	A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) in Elderly Patients With Metastatic Colorectal Cancer. Phase: Phase III Type: Treatment Status: Active Age: 70 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MO19286, NCT00484939
23.	A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma. Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BO20603, NCT00486759
24.	Phase III Randomized Study of Maintenance Therapy Comprising Bevacizumab in Patients Who Have Undergone First-Line Therapy for Metastatic Colorectal Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: SWS-SAKK-41/06, SAKK 41/06, EU-20762, NCT00544700
25.	BEVACIZUMAB + LETROZOL vs LETROZOL as First Line Treatment in Postmenopausal Patients With Advanced or Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: GEICAM/2006-11, Nº EudraCT: 2007-002841-19, NCT00545077